Who is sponsoring NCT05250596?

NCT05250596 is sponsored by Azienda USL Toscana Centro.

What drugs are being tested in NCT05250596?

Interventions in NCT05250596: Colchicine, Atorvastatin.

What condition does NCT05250596 study?

NCT05250596 studies Non ST Segment Elevation Acute Coronary Syndrome.

Is NCT05250596 still recruiting?

NCT05250596 is currently completed. Last updated 16 July 2024.

Last reviewed 2024-07-16 · How we verify

NCT05250596: COLOR-ACS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)

Completed Phase 2 Last updated 16 July 2024

What this trial tests

Phase 2 trial testing Colchicine in Non ST Segment Elevation Acute Coronary Syndrome in 182 participants. Completed in 30 May 2024.

Timeline

24 February 2022

Primary endpoint
24 February 2024

30 May 2024

Quick facts

Lead sponsor	Azienda USL Toscana Centro
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	182
Start date	24 February 2022
Primary completion	24 February 2024
Estimated completion	30 May 2024
Sites	3 locations across Italy

Drugs / interventions tested

Colchicine (COLCHICINE) — full drug profile →
Atorvastatin (atorvastatin) — full drug profile →

Conditions studied

Non ST Segment Elevation Acute Coronary Syndrome — all drugs for Non ST Segment Elevation Acute Coronary Syndrome →

Sponsor

Azienda USL Toscana Centro

Who can join

18 and older, any sex, with Non ST Segment Elevation Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since colchicine is known to have anti-inflammatory effects and inflammation is an early component of acute coronary syndrome (ACS), this study aims to evaluate the acute effects of low-dose colchicine, in addition to atorvastatin, administered on-admission to statin-naive patients with non-ST elevation ACS scheduled for early invasive strategy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.
Khan S, Huda B, Bhurka F, Patnaik R, et al · · 2025 · cited 7× · PMID 40943351 · DOI 10.3390/ijms26178429
Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study.
Toso A, Leoncini M, Magnaghi G, Biagini F, et al · · 2023 · cited 2× · PMID 36473121 · DOI 10.2459/jcm.0000000000001389
Anti-inflammatory therapy in atherosclerotic cardiovascular disease: Current reappraisal.
Muduli S, Gupta MD, Mp G, Yadav R. · · 2023 · cited 1× · PMID 37890557 · DOI 10.1016/j.ihj.2023.10.007

Verify or expand the search:

Other trials of Colchicine

Trials testing the same drug.

NCT07476625 — Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome · NA · not yet recruiting
NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements · Phase 3 · recruiting
NCT06203977 — Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) · Phase 1 · recruiting

Other recruiting trials for Non ST Segment Elevation Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06695429 — Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary · NA · recruiting
NCT06197724 — MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients · recruiting
NCT06255678 — Angio-based Final Functional Effect of PCI · recruiting
NCT05117866 — Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study · NA · active not recruiting

Other Azienda USL Toscana Centro trials

Trials by the same sponsor.

NCT06863896 — Laparoscopic Hartmann's Reversal Procedure: In the Absence of Standardized Guidelines, we Started a Database of Patient · not yet recruiting
NCT04141410 — Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05250596 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda USL Toscana Centro
Last refreshed: 16 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05250596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing